重组人类基因促红细胞生成素在治疗早产儿脑损伤中的应用

发布时间：2018-10-24 20:35

【摘要】：本研究将78例脑损伤早产儿根据随机数字表分为两组,其中对照组予以常规治疗,观察组予以重组人类基因促红细胞生成素治疗。对比两组治疗前后的NBNA、MDI、PDI评分,NSE、S-100B、BUN、Cr、SGPT、TBIL的水平变化,发现两组纠正胎龄40周时的NBNA评分较治疗前明显改善,且观察组的改善程度较对照组明显(p0.05)。两组在纠正胎龄3个月及6个月的MDI及PDI得分差异有统计学意义,观察组的改善程度较对照组明显,差异有统计学意义(p0.05)。两组治疗后的NSE和S-100B水平较治疗前降低,且观察组比对照组降低明显(p0.05)。两组治疗前后血清BUN、Cr、SGPT、TBIL水平差异无统计学意义(p0.05)。提示rhEPO对受损脑细胞有保护作用,可在一定程度上促进神经系统的修复,在改善早产儿脑损伤预后方面有着积极的作用。
[Abstract]:In this study, 78 premature infants with brain injury were divided into two groups according to random number table. The control group was treated with routine therapy and the observation group was treated with recombinant human gene erythropoietin. Comparing the NBNA,MDI,PDI score and NSE,S-100B,BUN,Cr,SGPT,TBIL level before and after treatment in both groups, it was found that the NBNA score at 40 weeks of corrected gestational age in the two groups was significantly improved than that before treatment, and the improvement degree in the observation group was significantly higher than that in the control group (p0.05). There were significant differences in MDI and PDI scores between the two groups at 3 and 6 months of corrected gestational age, and the improvement degree in the observation group was significantly higher than that in the control group (p0.05). The levels of NSE and S-100B in the two groups were significantly lower than those in the control group (p0.05). There was no significant difference in serum BUN,Cr,SGPT,TBIL levels between the two groups before and after treatment (p0. 05). The results suggest that rhEPO can protect the injured brain cells, promote the repair of nervous system to a certain extent, and play an active role in improving the prognosis of brain injury in premature infants.
【作者单位】：乐山职业技术学院;
【基金】：乐山职业技术学院提供项目资助
【分类号】：R722.6

【相似文献】